A University of California, Irvine research team has identified a critical factor in why advanced melanoma immunotherapy often loses its effectiveness, opening a path for more targeted future treatments. The team’s findings, published in the journal Cancer Research, point to the speed at which specific immune cells known as regulatory T cells, or Tregs, infiltrate tumors as the distinguishing factor between treatment success and disease recurrence.
Immunotherapy has changed outcomes for many cancer patients by enabling the body's immune system to target cancer cells. For patients with advanced melanoma, a particularly aggressive form of skin cancer, PD-1 blockade immunotherapy has transformed what were often terminal diagnoses into cases of long-term survival for some. However, these positive outcomes remain uncommon, with approximately 7 out of 10 melanoma patients experiencing disease recurrence even after initial treatment appeared effective.
Traditionally, investigating why immunotherapy fails and identifying solutions has been a slow and resource-intensive process, typically involving testing one hypothesis at a time in laboratory settings, which can take years and substantial funding. The UCI research team pursued a different method, first building a mathematical model of tumor and immune cell interactions, then using the model to pinpoint the most likely mechanism of resistance.
Francesco Marangoni, a cancer immunologist and assistant professor of physiology and biophysics, stated, "We integrated two entirely distinct disciplines – mathematics and biology – and enabled them to inform one another." He collaborated with co-senior investigator John Lowengrub, a Distinguished Professor of mathematics, biomedical engineering, and systems biology, and Rachel Sousa, a graduate student researcher and the study’s first author.
The research focused on the complex interactions within a tumor. Effector T cells are the immune system's primary weapon against cancer. Regulatory T cells (Tregs) normally prevent the immune system from attacking healthy tissue, but in cancer, they can protect tumors by suppressing effector T cells. Tumor cells further defend themselves by displaying PD-L1 protein, which binds to PD-1 on effector T cells, effectively shutting them down. PD-1 blockade immunotherapy thwarts this interaction, reactivating effector T cells, but it can also unintentionally strengthen Treg activity, helping to restore the immunosuppressive environment it was designed to overcome.
The UCI researchers translated these cellular interactions into a system of mathematical equations, drawing on decades of published cancer research. They validated this model against experimental data from mice with melanoma, refining its predictions until they aligned with observed outcomes. With the model demonstrating sufficient accuracy, the team used it to generate 342 virtual mice with melanoma, simulating natural biological variation seen in real populations.
After simulating PD-1 blockade immunotherapy across all virtual mice, researchers compared those that responded favorably with those that experienced disease recurrence. Among more than 30 biological parameters in the model, the speed at which Tregs entered the tumor emerged as the most consistent distinguishing factor. Sousa noted that the mathematical analysis pointed directly to one variable, indicating that "the rate of Treg infiltration into the tumor was the critical factor."
To experimentally validate this prediction, the team engineered mice where Tregs migrated inefficiently into tumors, while the rest of the immune system remained intact. These animals were then treated with PD-1 blockade immunotherapy. The combined intervention substantially outperformed PD-1 blockade alone, nearly doubling survival duration and slowing tumor growth in mice whose cancer was not fully eliminated. Lowengrub commented that the agreement between model prediction and experiments is exciting because it points toward a promising new strategy for improving PD-1 blockade immunotherapy outcomes.
This study does not represent an immediate treatment for patients. Instead, it offers a faster, more cost-efficient framework for determining which therapeutic strategies merit further development. For melanoma specifically, this research strengthens interest in a therapeutic strategy already under consideration: simultaneously targeting Treg infiltration of the tumor while employing PD-1 blockade immunotherapy. Earlier attempts at Treg inhibition faced complications due to off-target effects on beneficial immune cells. This study suggests that more selective interventions, capable of targeting only the tumor-protective Treg population, could be a more promising direction for future clinical investigation.
Beyond its immediate findings, the mathematical model itself is a reusable platform. It can be used by researchers to test the efficacy of other treatments, individually or in combination, and to explore other mechanisms of therapy resistance.
